Associated Papers
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.
Shi Y et al.
Ebiomedicine, 2020
32304999 (PubMed )
Supplement: mmc1.xlsx › 4.mutations
Rational design of non-resistant targeted cancer therapies.
Martínez-Jiménez F et al.
Scientific Reports, 2017
ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
Goetz EM et al.
Cancer Research, 2014
Select a paper to view details